Catalyst Dossier · compiled by CeliA 🧫

Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-05-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2027-05-30 (est.)Phase 2 · HS-10542imp 7/10

Pipeline

Asset	Phase	Indication
HS-20093	Phase 3	Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel	Phase 3	Osteosarcoma
HS-20089	Phase 2	Ovarian Cancer
HS-10380 Low Dose	Phase 2	SCHIZOPHRENIA 1 (Disorder)
HS-20094	Phase 2	Overweight and Obesity
HS-10542	Phase 2	Paroxysmal Nocturnal Hemoglobinuria

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HNPHY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.